Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr:115:104958.
doi: 10.1016/j.oraloncology.2020.104958. Epub 2021 Feb 11.

cfDNA detection for HPV+ squamous cell carcinomas

Affiliations
Review

cfDNA detection for HPV+ squamous cell carcinomas

Kate Chatfield-Reed et al. Oral Oncol. 2021 Apr.

Abstract

High-risk human papillomavirus (HPV) is an etiologic factor in a spectrum of squamous cell carcinomas including anal, cervical, and oropharyngeal. HPV cell free DNA (cfDNA) is shed from the primary tumor into systemic circulation and can be detected using several platforms including quantitative PCR, digital droplet PCR, or next generation sequencing. Levels of HPV cfDNA at time of initial presentation is associated with known poor prognostic clinicopathologic variables, such as advanced stage and, locoregional and distant metastases. Moreover, longitudinal sampling revealed that persistent or increasing HPV cfDNA levels are indicative of treatment relapse and, in some studies, HPV cfDNA detection predicted treatment failures prior to routine post-treatment clinical imaging. A liquid biopsy platform using HPV cfDNA offers unique advantages over traditional approaches and may have clinical utility for detection of minimum residual disease, treatment response, and disease progression in patients with HPV+ cancers.

Keywords: Biomarker; Early detection; HPV; Liquid biopsy; ddPCR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Similar articles

Cited by

References

    1. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type: Worldwide burden of cancer attributable to HPV. International Journal of Cancer 2017;141:664–70. 10.1002/ijc.30716. - DOI - PMC - PubMed
    1. Goodman MT, Saraiya M, Thompson TD, Steinau M, Hernandez BY, Lynch CF, et al. Human Papillomavirus Genotype and Oropharynx Cancer Survival in the United States. Eur J Cancer 2015;51:2759–67. 10.1016/j.ejca.2015.09.005. - DOI - PMC - PubMed
    1. Alemany L, Saunier M, Alvarado I, Quirós B, Salmeron J, Shin H, et al. HPV DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015;136:98–107. 10.1002/ijc.28963. - DOI - PMC - PubMed
    1. Varier I, Keeley BR, Krupar R, Patsias A, Dong J, Gupta N, et al. Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non–human papillomavirus16 viral subtypes. Head & Neck 2016;38:1330–7. 10.1002/hed.24442. - DOI - PubMed
    1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology 1999;189:12–9. 10.1002/(SICI)10969896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. - DOI - PubMed

Publication types

LinkOut - more resources